Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry

BMC Cancer

Table 1 Patient data by gender

	Females	Males	All patients
Total cohort (N)	587	628	1215
Missing date of birth (n)	9	12	21
Missing date of diagnosis (n)	5	7	12
Median age at diagnosis in years [range]	50.5 [5.4-92.2]	52.6 [10.0-90.0]	51.7 [5.4-92.2]
Median follow-up time in years [range]	4.5 [0-39.5]	5.8 [0-30.6]	5.2 [0-39.5]
Death events (n)	117	195	312
Total survival cohort (n)	578	617	1195
Primary tumor location (n)	523	565	1088
Tumor site, survival (n)	519	556	1075
Disease status at diagnosis (n)	587	628	1215
Disease status, survival analyses (n)	578	617	1195
Confidence in no metastatic/advanced disease report (see methods for description)
High confidence	114	100	214
Intermediate confidence	102	96	198
Low confidence	5	12	17
Report of metastatic/advanced disease	366	420	786
Mutation data (n)	164	161	325
Mutation, survival (n)	164	160	324
Continent of birth (n)
N. America	468	489	957
Europe	69	71	140
Asia	30	43	73
Oceania	7	9	16
S. America	6	10	16
Africa	6	3	9
Unknown	1	3	4

Patients missing a date of birth were not included in analyses based on age at diagnosis (n = 21). Follow-up was calculated from date of diagnosis until date of last update (or endpoint) in years. Survival cohort and sub-groups includes those patients for which overall survival could be estimated. Continents of birth were grouped post hoc from reported country of birth

ISSN: 1471-2407